Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-6766 Alone or With Everolimus in Solid Tumours and Multiple Myeloma
NCT02407509Phase 1Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jun 2013
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of avutometinib in solid tumor, multiple myeloma (MM), lung cancer and 1 more (10 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Recommended Phase 2 Dose of VS-6766 at 28 days, Recommended Phase 2 Dose of VS-6766 and Everolimus at 28 days and 2 more. Started Jun 2013; status: completed.
02
Drugs
avutometinib
03
Conditions
solid tumormultiple myeloma (MM)lung cancerovarian cancer
Beyond the preview
Go deeper on NCT02407509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02407509.